Baker Bros. Advisors as of Dec. 31, 2012
Portfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 68 positions in its portfolio as reported in the December 2012 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
BioMarin Pharmaceutical (BMRN) | 3.7 | $9.9M | 200k | 49.20 | |
Medivation | 3.5 | $9.5M | 967k | 9.78 | |
BioDelivery Sciences International | 3.4 | $9.2M | 2.1M | 4.31 | |
Xoma | 3.2 | $8.7M | 20M | 0.43 | |
Synergy Pharmaceuticals | 3.2 | $8.6M | 1.6M | 5.26 | |
Exelisis 4.25% 8/15/2019 conv bonds | 3.2 | $8.6M | 19M | 0.45 | |
XenoPort | 3.0 | $8.0M | 1.0M | 7.77 | |
Gilead 0.625% 5/1/13 conv bonds | 3.0 | $8.0M | 25M | 0.32 | |
BioCryst Pharmaceuticals (BCRX) | 2.9 | $7.9M | 5.6M | 1.42 | |
Clovis Oncology | 2.9 | $7.8M | 1.1M | 7.03 | |
Seattle Genetics | 2.9 | $7.7M | 19M | 0.40 | |
Synageva Biopharma | 2.6 | $7.1M | 8.4M | 0.85 | |
Intermune | 2.6 | $7.1M | 1.8M | 4.01 | |
Mei Pharma | 2.6 | $7.0M | 1.0M | 7.00 | |
Spectrum Pharmaceuticals | 2.5 | $6.8M | 1.5M | 4.52 | |
Gilead Sciences (GILD) | 2.5 | $6.8M | 92k | 73.45 | |
Threshold Pharma | 2.5 | $6.7M | 1.6M | 4.21 | |
Cerus Corporation (CERS) | 2.5 | $6.7M | 2.1M | 3.16 | |
Genomic Health | 2.5 | $6.7M | 12M | 0.54 | |
Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 conv bonds | 2.5 | $6.6M | 23M | 0.29 | |
Gilead 1.625% 5/1/16 conv bonds | 2.3 | $6.2M | 22M | 0.29 | |
Incyte | 2.3 | $6.1M | 15M | 0.41 | |
Aegerion Pharmaceuticals | 2.1 | $5.6M | 615k | 9.11 | |
Array BioPharma | 2.1 | $5.6M | 1.5M | 3.72 | |
Viropharma | 2.0 | $5.4M | 9.0M | 0.60 | |
Derma Sciences | 1.9 | $5.1M | 1.4M | 3.75 | |
Kythera Biopharmaceuticals I | 1.9 | $5.0M | 165k | 30.34 | |
Anacor Pharmaceuticals | 1.5 | $4.0M | 777k | 5.20 | |
Intermune Inc Notes 5% 3/1/15 conv bonds | 1.4 | $3.7M | 34M | 0.11 | |
ArQule | 1.3 | $3.6M | 1.3M | 2.79 | |
Repros Therapeutics | 1.3 | $3.6M | 1.5M | 2.40 | |
Synta Pharmaceuticals | 1.2 | $3.2M | 1.5M | 2.18 | |
Intercept Pharmaceuticals In | 1.1 | $2.8M | 375k | 7.57 | |
54 Intermune Inc Notes 2.5% 9/15/18 conv bonds | 1.0 | $2.8M | 17M | 0.17 | |
Salix Pharmaceuticals | 1.0 | $2.7M | 67k | 40.47 | |
Progenics Pharmaceuticals | 1.0 | $2.7M | 900k | 2.98 | |
United Therapeutics Notes 1% 9/15/16 144a conv bonds | 1.0 | $2.7M | 18M | 0.15 | |
Zogenix | 1.0 | $2.7M | 2.0M | 1.33 | |
Acadia Pharmaceuticals | 1.0 | $2.7M | 16M | 0.17 | |
INC Ventrus Biosciences | 1.0 | $2.6M | 1.2M | 2.16 | |
D Tranzyme | 0.9 | $2.4M | 4.4M | 0.54 | |
Chelsea Therapeutics International | 0.9 | $2.3M | 3.0M | 0.76 | |
Onyx Pharmaceuticals | 0.8 | $2.1M | 160k | 12.90 | |
Amicus Therapeutics (FOLD) | 0.8 | $2.1M | 765k | 2.68 | |
23 Halozyme Therapeutics | 0.7 | $1.9M | 1.8M | 1.06 | |
Cytrx | 0.7 | $1.9M | 1.0M | 1.87 | |
Vanda Pharmaceuticals (VNDA) | 0.7 | $1.9M | 500k | 3.70 | |
Discovery Laboratories | 0.7 | $1.8M | 853k | 2.11 | |
Insmed (INSM) | 0.6 | $1.6M | 240k | 6.69 | |
Ligand Pharmaceuticals | 0.6 | $1.5M | 73k | 20.74 | |
Qlt | 0.6 | $1.5M | 1.5M | 1.01 | |
Geron Corporation (GERN) | 0.5 | $1.4M | 1.0M | 1.41 | |
Vertex Pharmaceuticals Notes 3.35% 10/1/15 conv bonds | 0.5 | $1.4M | 28M | 0.05 | |
Durata Therapeutics | 0.5 | $1.3M | 169k | 7.64 | |
Biodel | 0.5 | $1.3M | 540k | 2.35 | |
Pharmacyclics | 0.5 | $1.3M | 11M | 0.11 | |
Infinity Pharmaceuticals | 0.5 | $1.2M | 1.2M | 1.06 | |
Medivation 2.625% 4/1/17 conv bonds | 0.5 | $1.2M | 25M | 0.05 | |
ZIOPHARM Oncology | 0.4 | $1.1M | 254k | 4.16 | |
Auxilium | 0.4 | $1.0M | 4.4M | 0.24 | |
Lpath | 0.4 | $1.0M | 200k | 5.05 | |
Ariad Pharmaceuticals | 0.3 | $830k | 2.1M | 0.39 | |
Chemocentryx | 0.2 | $547k | 50k | 10.94 | |
Cubist Pharmaceuticals | 0.1 | $210k | 5.0k | 42.00 | |
Cyclacel Pharmaceuticals Inc pfd conv ex 6% (CYCCP) | 0.0 | $105k | 21k | 5.01 | |
Idera Pharmaceuticals | 0.0 | $79k | 89k | 0.89 | |
Sequenom | 0.0 | $61k | 13k | 4.73 | |
Aradigm Corporation (ARDM) | 0.0 | $13k | 100k | 0.13 |